Key Takeaways:
Star Sports Med (01609.HK) saw its Hong Kong initial public offering oversubscribed by 7,823.13 times, indicating massive retail investor interest ahead of its trading debut.
The company, a medical device firm focused on sports medicine, attracted four cornerstone investors, including JSC International and OrbiMed Asia IV, who subscribed for a combined 2.9229 million shares.
The offer price was finalized at HKD 98.5 per share, with the company set to receive net proceeds of HKD 758 million. The international portion of the offering was oversubscribed by 10.41 times. The success rate for applicants seeking one lot of 50 shares was just 1.5 percent.
Shares are expected to begin trading on Tuesday. The intense demand comes despite the clawback mechanism not being triggered, concentrating the small public float among a large number of investors.
Star Sports Med offered a total of 8.2418 million shares globally, with 10 percent allocated to the Hong Kong public. The strong cornerstone backing, accounting for 34.7% of the offering, provided a solid foundation for the deal.
The pricing gives the company a significant valuation, which will be tested in its first day of trading. Investors will be watching to see if the initial retail frenzy translates into sustained market demand, with the cornerstone shares locked up until November 4, 2026.
This article is for informational purposes only and does not constitute investment advice.
